Frontiers | High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
Overall survival depends on tumor subtype and systemic treatment. a... | Download Scientific Diagram
Breast cancer survival in Mexico between 2007 and 2016 in women without social security: a retrospective cohort study - The Lancet Regional Health – Americas
Breast Cancer Types | Breast Cancer Trials
Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes | BMC Women's Health | Full Text
Relapse-free survival in luminal A-like versus luminal B-like breast... | Download Scientific Diagram
Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes - Sereda - Translational Breast Cancer Research
Frontiers | High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study
Breast Cancer Subtypes And Prognosis | BCTT
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer | npj Breast Cancer
Breast cancer-specific survival by body mass index categories for... | Download Scientific Diagram
Frontiers | Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
Breast Cancer Subtypes And Prognosis | BCTT
:max_bytes(150000):strip_icc()/GettyImages-1164234982-17a305f7dbaf4f4fb29ca25003cde65b.jpg "Luminal A Breast Cancer: Causes, Diagnosis, and Treatment")
Luminal A Breast Cancer: Causes, Diagnosis, and Treatment
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes - Sereda - Translational Breast Cancer Research
Integrative analysis identifies two molecular and clinical subsets in Luminal B breast cancer - ScienceDirect
Cancers | Free Full-Text | Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone
Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint - Agendia
The influence of breast cancer subtype on survival after palliative radiation for osseous metastases - Abdelhakiem - 2020 - Cancer Medicine - Wiley Online Library
Luminal B Breast Cancer: Symptoms, Diagnosis, and Treatment
